MetaVia (MTVA) Stock: Buy, Sell, or Hold?
MTVA - MetaVia Inc. Common Stock
$1.66
-0.09 (-5.14%)
âŧ
5d:
-9.78%
30d:
+12.93%
90d:
-17.41%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When MTVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: MTVA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: MTVA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: MTVA is currently trading at $1.66, which is considered slightly high relative to its 30-day fair value range of $1.44 to $1.70.
Technical Outlook: Technically, MTVA is showing sideways momentum. Immediate support is located at $1.52, while resistance sits at $1.93. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: MTVA scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.33 (+1064.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MTVA is showing sideways momentum. Immediate support is located at $1.52, while resistance sits at $1.93. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: MTVA scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.33 (+1064.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.44 -
$1.70
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
36.8%
All Signals
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.1%)
- BULLISH: Trading 1064.7% below Wall St target ($19.33)
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.44 -
$1.70
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.52
Resistance Level
$1.93
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.70
Wall Street Target
$19.33
(+1064.7%)
Share & Embed Analysis
Last updated: September 13, 2026 11:02 AM ET
Data refreshes hourly during market hours. Next update: 12:02 PM
Data refreshes hourly during market hours. Next update: 12:02 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MTVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$27 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
